Who Exports Atorvastatin from India — 477 Suppliers Behind a $1.1B Market
India's atorvastatin export market is supplied by 477 active exporters who collectively shipped $1.1B across 15,000 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 24.6% market share, followed by PIRAMAL PHARMA LIMITED and MYLAN LABORATORIES LIMITED. The top 5 suppliers together control 73.2% of total export value, reflecting a concentrated market structure.
Top Atorvastatin Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading atorvastatin exporter from India, holding a 24.6% share of the $1.1B market across 15,000 shipments from 477 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, PIRAMAL PHARMA LIMITED, MYLAN LABORATORIES LIMITED, MSN LABORATORIES PRIVATE LIMITED, ALKEM LABORATORIES LIMITED — collectively control 73.2% of total export value, indicating a highly concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (24.6%), PIRAMAL PHARMA LIMITED (22.4%), MYLAN LABORATORIES LIMITED (14.6%), MSN LABORATORIES PRIVATE LIMITED (7.7%), ALKEM LABORATORIES LIMITED (3.8%).
Top Atorvastatin Exporters from India
Ranked by export value · 477 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED PH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T]ATORVASTATIN 80 MG TABLETS(ATORVASTATINA | $265.9M | 10 | 24.6% |
| 2 | PIRAMAL PHARMA LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKS | $241.6M | 1 | 22.4% |
| 3 | MYLAN LABORATORIES LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSPH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $158.2M | 7 | 14.6% |
| 4 | MSN LABORATORIES PRIVATE LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSATORVASTATIN 20 MG TABS( BRELVASTIN 20 MATORVASTATIN 80 MG TABLETS(ATORVASTATINA | $83.7M | 20 | 7.7% |
| 5 | ALKEM LABORATORIES LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSATORVASTATINA 20 (ATORVASTATINA 20 | $41.5M | 5 | 3.8% |
| 6 | UMEDICA LABORATORIES PRIVATE LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSATORVASTATIN 20 MG TABS( BRELVASTIN 20 MATORVASTATIN TAB 40 MG X 28'S MSN UK | $39.3M | 8 | 3.6% |
| 7 | AUROBINDO PHARMA LTD PH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T]ATORVASTATIN 80 MG TABLETS(ATORVASTATINA | $33.2M | 11 | 3.1% |
| 8 | SUN PHARMACEUTICAL INDUSTRIES LIMITED PH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T]ATORVASTATIN CALCIUM TABLETS 80MG ( ATOR | $32.8M | 18 | 3.0% |
| 9 | GRAVITI PHARMACEUTICALS PRIVATE LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKS | $24.0M | 1 | 2.2% |
| 10 | MEDREICH LIMITED PH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T]ATORVASTATIN TAB 40 MG X 28'S MSN UK | $15.3M | 6 | 1.4% |
| 11 | MICRO LABS LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSATORVASTATIN 20 MG TABS( BRELVASTIN 20 MATORVASTATIN 80 MG TABLETS(ATORVASTATINA | $13.7M | 22 | 1.3% |
| 12 | BIOCON PHARMA LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKS | $13.1M | 2 | 1.2% |
| 13 | JUBILANT GENERICS LIMITED ATORVASTATIN TABLETS 10MG (ATORVASTATINATORVASTATIN TABLETS 10MG ATORVASTATINATORVASTATIN TABLETS 10 MG, | $12.8M | 1 | 1.2% |
| 14 | APOTEX RESEARCH PRIVATE LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKSPH.DRU.& MED.: ACH-ATORVASTATIN 20MG TABLETS [8315X1X500T]PH.DRU.& MED.: ACH-ATORVASTATIN 40MG TABLETS [2122X1X500T] | $8.4M | 1 | 0.8% |
| 15 | ANNORA PHARMA PRIVATE LIMITED ATORVASTATIN CALCIUM TABLETS USP 40 MG 500BT 13536 PACKS | $8.4M | 1 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Atorvastatin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter, December | Yes, April 2007 | Yes | Not verified | Received EU GMP certification in April 2007; FDA issued a warning letter in Dece |
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
| MSN Laboratories Private Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
| Aurobindo Pharma Ltd | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
| Alkem Laboratories Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
| Biocon Pharma Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
| Jubilant Generics Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
| Apotex Research Private Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and WHO GMP certification; no FDA warning letters r |
TransData Nexus reviewed the regulatory standing of 9 leading Atorvastatin exporters from India. 8 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Atorvastatin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts numerous Active Pharmaceutical Ingredient (API) manufacturers, including companies like SVK Laboratories Private Limited, which specializes in bulk drugs and intermediates. This concentration of API producers makes Hyderabad a pivotal hub for sourcing raw materials essential for Atorvastatin production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. This region houses major companies like Alembic Pharmaceuticals, which specializes in formulations for therapeutic areas such as cardiology. The presence of such companies underscores the region's capacity in producing finished pharmaceutical products, including Atorvastatin formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. Its proximity to major ports facilitates efficient international distribution. Companies in this region benefit from well-established logistics and regulatory frameworks, enhancing their ability to export Atorvastatin to key markets such as the United States and Canada.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is known for its tax incentives, attracting numerous pharmaceutical manufacturers. This zone offers cost advantages in production, making it an attractive location for companies producing Atorvastatin. The region's infrastructure supports large-scale manufacturing, contributing significantly to the pharmaceutical supply chain.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Leverage Cost Advantages: Utilize the tax incentives and lower production costs in regions like Baddi-Nalagarh to optimize procurement expenses.
- Ensure Regulatory Compliance: Collaborate with manufacturers in clusters known for stringent quality standards, such as Ahmedabad-Vadodara, to meet international regulatory requirements.
- Optimize Logistics: Partner with companies in the Mumbai-Thane-Raigad region to benefit from efficient export logistics and reduced lead times.
By strategically sourcing from these diverse pharmaceutical clusters, companies can enhance the resilience and efficiency of their Atorvastatin supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Atorvastatin exporters from India
Piramal Pharma Limited — Piramal Pharma acquires peptide API-maker Hemmo Pharmaceuticals
Piramal Pharma Solutions, a division of Piramal Pharma Limited, completed the acquisition of Hemmo Pharmaceuticals, a leading manufacturer of peptide active pharmaceutical ingredients (APIs). This strategic move aims to enhance Piramal's capabilities in the peptide API segment. - IMPACT: The acquisition is expected to strengthen Piramal Pharma's position in the API market, potentially increasing its Atorvastatin export capacity.
Impact: The acquisition is expected to strengthen Piramal Pharma's position in the API market, potentially increasing its Atorvastatin export capacity.
Piramal Pharma Limited — Piramal Pharma completes full acquisition of Convergence Chemicals
Piramal Pharma Limited completed the acquisition of Convergence Chemicals, aiming to bolster its manufacturing capabilities and expand its product portfolio. - IMPACT: This acquisition may enhance Piramal Pharma's production capacity, potentially impacting its Atorvastatin exports.
Impact: This acquisition may enhance Piramal Pharma's production capacity, potentially impacting its Atorvastatin exports.
Amneal Pharmaceuticals — Amneal Pharmaceuticals acquires Punishka Healthcare
Amneal Pharmaceuticals acquired Punishka Healthcare, expanding its manufacturing capacity for injectable medicines. - IMPACT: While Amneal is not listed among the top Atorvastatin exporters, this acquisition could influence the competitive landscape in the pharmaceutical export market.
Impact: While Amneal is not listed among the top Atorvastatin exporters, this acquisition could influence the competitive landscape in the pharmaceutical export market.
Common Questions — Atorvastatin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which atorvastatin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 328 recorded shipments worth $265.9M. PIRAMAL PHARMA LIMITED (429 shipments) and MYLAN LABORATORIES LIMITED (330 shipments) are also established high-volume exporters.
Q How many atorvastatin manufacturers are there in India?
India has 477 active atorvastatin exporters with a combined export market of $1.1B across 15,000 shipments to 145 countries. The top 5 suppliers hold 73.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for atorvastatin from India?
Average FOB unit price: $6.13 per unit, ranging from $0.00 to $5113.40. Average shipment value: $72.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 477 verified Indian exporters of Atorvastatin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 15,000 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 145 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
15,000 Verified Shipments
477 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists